Skip to main content
SpringerLink
Log in

Delavirdine mesylate salvage therapy worth it after indinavir failure

  • Meeting report
  • Published:
PharmacoEconomics & Outcomes News

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Rights and permissions

Reprints and permissions

About this article

Cite this article

Delavirdine mesylate salvage therapy worth it after indinavir failure. Pharmacoecon. Outcomes News 377, 3–4 (2002). https://doi.org/10.1007/BF03279501

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF03279501

Keywords

Search

Navigation